Quantity of qualified sufferers: CDEC reviewed the uncertainty in the volume of people with reasonably intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who will be classified as having moderate or reasonable ailment could possibly have a sig